CA-based biotechnology startup CRISPR QC secures series A round funding. The deal’s total value was not made public. The CRISPR Analytics Platform will continue to advance thanks to funding from Xcellerant Ventures.
Read also – Tenn-based Reimagine Care Secures an Investment
Under the leadership of Ross Bundy, CRISPR QC uses its analytics platform to offer thorough measurements and analysis regarding CRISPR activity, empowering researchers and scientists to maximise the results of gene editing while maintaining the highest standards of quality control.
Read also – Cambridge-based Ceretype Neuromedicine Secures its Second Round of Seed Funding
The platform is based on CRISPR-Chip technology, a proprietary technology of the company that enables direct and instantaneous measurement of CRISPR activity.
About CRISPR QC
Here at CRISPR QC, we provide the essential knowledge and understanding needed to fully utilise CRISPR in order to enable scientists to use it to address the world’s most pressing issues.
Read also – Moonwalk Biosciences Raises $57 Mn Seed and Series A Funding
